ATE321135T1 - Verfahren zur diagnose und behandlung neurologischer erkrankungen - Google Patents

Verfahren zur diagnose und behandlung neurologischer erkrankungen

Info

Publication number
ATE321135T1
ATE321135T1 AT99960975T AT99960975T ATE321135T1 AT E321135 T1 ATE321135 T1 AT E321135T1 AT 99960975 T AT99960975 T AT 99960975T AT 99960975 T AT99960975 T AT 99960975T AT E321135 T1 ATE321135 T1 AT E321135T1
Authority
AT
Austria
Prior art keywords
diagnosis
treatment
neurological diseases
seq
nucleic acid
Prior art date
Application number
AT99960975T
Other languages
English (en)
Inventor
Roger Nitsch
Isabell Greeve
Original Assignee
Evotec Neurosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh filed Critical Evotec Neurosciences Gmbh
Application granted granted Critical
Publication of ATE321135T1 publication Critical patent/ATE321135T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
AT99960975T 1998-11-12 1999-11-12 Verfahren zur diagnose und behandlung neurologischer erkrankungen ATE321135T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98121478A EP1002862A1 (de) 1998-11-12 1998-11-12 Verfahren zur Diagnose oder Behandlung neurologischer Krankheiten

Publications (1)

Publication Number Publication Date
ATE321135T1 true ATE321135T1 (de) 2006-04-15

Family

ID=8232965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960975T ATE321135T1 (de) 1998-11-12 1999-11-12 Verfahren zur diagnose und behandlung neurologischer erkrankungen

Country Status (8)

Country Link
US (2) US20050239169A1 (de)
EP (2) EP1002862A1 (de)
JP (1) JP4663121B2 (de)
AT (1) ATE321135T1 (de)
DE (1) DE69930545T2 (de)
DK (1) DK1129191T3 (de)
ES (1) ES2262352T3 (de)
WO (1) WO2000029569A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002525081A (ja) * 1998-08-27 2002-08-13 クォーク・バイオテク・インコーポレーテッド 低酸素により調節される遺伝子転写に特徴的な配列
NZ526617A (en) * 2000-11-28 2004-09-24 Wyeth Corp Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
JP4129229B2 (ja) * 2001-05-31 2008-08-06 千葉県 神経芽細胞腫において単離された核酸
EP1410013A4 (de) * 2001-06-21 2006-02-01 Millennium Pharm Inc Zusammensetzungen, kits und verfahren zur identifizerung, beurteilung, vorbeugung und therapie von brust- und eierstockkrebs
AU2003242588A1 (en) * 2002-05-28 2003-12-12 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US11208256B2 (en) * 2018-04-13 2021-12-28 Seung Il Corporation Spraying vessel capable of relieving overpressure and valve assembly thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814157A3 (de) * 1996-06-18 1998-01-07 Smithkline Beecham Corporation Diagnostischer Masker für Varianten von Presenilin Genen, verbunden mit alzheimerischen Krankheit und familiären erwachsenen Einsetzens alzheimerischen Krankheit
JP2002525081A (ja) * 1998-08-27 2002-08-13 クォーク・バイオテク・インコーポレーテッド 低酸素により調節される遺伝子転写に特徴的な配列

Also Published As

Publication number Publication date
EP1129191A1 (de) 2001-09-05
DE69930545D1 (de) 2006-05-11
US20050239169A1 (en) 2005-10-27
WO2000029569A1 (en) 2000-05-25
EP1002862A1 (de) 2000-05-24
US20080261302A1 (en) 2008-10-23
DK1129191T3 (da) 2006-07-17
ES2262352T3 (es) 2006-11-16
EP1129191B1 (de) 2006-03-22
JP4663121B2 (ja) 2011-03-30
DE69930545T2 (de) 2007-03-08
JP2002530076A (ja) 2002-09-17

Similar Documents

Publication Publication Date Title
EP1361229A3 (de) Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
CY1116682T1 (el) Διπλασιασμος-μυϊκης μαζας σε θηλαστικα
ATE244304T1 (de) Verfahren zur veränderung des essverhaltens, dafür verwendbare verbindungen und dna, die einen hypothalamischen atypischen neuropeptid y/peptid yy rezeptor (y5) kodiert
EP1439230A3 (de) Menschliche transmembranprotein TMP-2 gen
DE69233736D1 (de) Phosphorylierungsepitope aus dem Tau-Protein zur Diagnose und Behandlung der Alzheimer-Krankheit
ATE355009T1 (de) Auf einem abonnement basierendes biosensorüberwachungsverfahren
TR200103297T2 (tr) Nöral ve renal gelişmenin uyarılması için Ret ligandı (RetL)
DE69929882D1 (de) Verfahren und vorrichtung zur nukleinsäurereinigung
ATE227343T1 (de) Protease und verwandte dns-verbindungen
DE60028544D1 (de) Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs
ATE321135T1 (de) Verfahren zur diagnose und behandlung neurologischer erkrankungen
DE69729954D1 (de) Identifizierungsverfahren für Substanzen die an das Pyk2 Polypeptid binden
DE69634438D1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
DE69929787D1 (de) Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
PT920501E (pt) Neuritina um neurogene
DE69628702D1 (de) Höckerelektrode für Transistor und Verfahren zur Herstellung
DE69904078D1 (de) Verfahren und vorrichtung zur herstellung von einstückigen gummiraupenketten für traktoren
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
ATE335759T1 (de) Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind.
DE3885304D1 (de) Zubereitung für zahnbehandlung und verfahren zur herstellung.
DE69532964D1 (de) Neue proteine aus ektoparasitenspeichel und vorrichtung zur sammlung davon
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
ATE312914T1 (de) Rdgb-proteine
DE59904268D1 (de) Verfahren zur Herstellung von Polyamid 6 für Spinnzwecke
DE59805514D1 (de) Verfahren zur herstellung von monofilamenten aus polyamid und monofilament für technische gewebe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1129191

Country of ref document: EP